Logotype for CorMedix Inc

CorMedix (CRMD) investor relations material

CorMedix Morgan Stanley 23rd Annual Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for CorMedix Inc
Morgan Stanley 23rd Annual Global Healthcare Conference summary10 Sep, 2025

Business transformation and strategic acquisitions

  • Recent acquisition of Millenta transformed the company from a single-product to a multi-product business, adding a stable base of approved anti-infective drugs and significant growth potential, especially with Roseo.

  • Millenta acquisition expected to deliver $35–$45 million in annual synergies within 12 months, with a focus on operational and non-personnel cost savings.

  • Integration efforts are underway to unify commercial teams and optimize product promotion in hospital and acute care settings.

  • Recent investment in Telferra provides a right of first negotiation for a promising ICU anticoagulant, with phase 3 data expected in early 2026.

  • Capital allocation will prioritize opportunities with near-term accretion, commercial synergy, and growth, mirroring Millenta’s criteria.

Product updates and market adoption

  • DefenCath, the lead product, launched commercially in July 2024, targeting hemodialysis patients to prevent bloodstream infections; adoption has been strong among major dialysis providers.

  • Guidance for 2025 DefenCath revenue was raised to $200–$250 million, driven by robust uptake among non-LDO customers and growing LDO adoption.

  • DefenCath is the only FDA-approved antimicrobial catheter lock solution, offering a unique combination of heparin and taurolidine with broad-spectrum activity and a strong safety profile.

  • Real-world evidence studies are underway to support broader reimbursement, especially with Medicare Advantage payers.

  • Expansion into additional indications, such as TPN and oncology, is in progress, with TPN phase 3 study on track for completion by end of 2026 and potential label by end of 2027.

Pipeline and growth opportunities

  • Roseo, acquired via Millenta, is in phase 3 for prophylaxis in immunocompromised patients, with commercialization targeted for early 2027 if successful.

  • Roseo offers potential advantages over current standards of care, including fewer drug interactions and lower toxicity.

  • Other Millenta products, such as Minocin and VaporMir, show stable or modest growth, while Commerza is being considered for a relaunch.

  • DefenCath’s label expansion into TPN and oncology could unlock significant new markets, with TPN representing a $500–$750 million opportunity.

  • Additional pipeline opportunities are being explored, with a focus on synergistic hospital-based products.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next CorMedix earnings date

Logotype for CorMedix Inc
Q3 202529 Oct, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next CorMedix earnings date

Logotype for CorMedix Inc
Q3 202529 Oct, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infections and other complications associated with the use of catheters in dialysis and other medical settings. The company's lead product, Defencath, is an anti-infective solution designed to reduce the risk of catheter-related bloodstream infections. CorMedix is dedicated to addressing unmet medical needs in infection prevention and enhancing patient care. The company is headquartered in Berkeley Heights, New Jersey, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage